BR112022016614A2 - Composições e métodos de uso dos mesmos para o tratamento de doenças neurodegenerativas e mitocondriais - Google Patents
Composições e métodos de uso dos mesmos para o tratamento de doenças neurodegenerativas e mitocondriaisInfo
- Publication number
- BR112022016614A2 BR112022016614A2 BR112022016614A BR112022016614A BR112022016614A2 BR 112022016614 A2 BR112022016614 A2 BR 112022016614A2 BR 112022016614 A BR112022016614 A BR 112022016614A BR 112022016614 A BR112022016614 A BR 112022016614A BR 112022016614 A2 BR112022016614 A2 BR 112022016614A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- neurodegenerative
- compositions
- treatment
- mitochondrial diseases
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 208000012268 mitochondrial disease Diseases 0.000 title abstract 3
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000000626 neurodegenerative effect Effects 0.000 title abstract 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 abstract 2
- 208000031229 Cardiomyopathies Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 101000605835 Homo sapiens Serine/threonine-protein kinase PINK1, mitochondrial Proteins 0.000 abstract 1
- 102100038376 Serine/threonine-protein kinase PINK1, mitochondrial Human genes 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
- G01N33/5079—Mitochondria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
COMPOSIÇÕES E MÉTODOS DE USO DOS MESMOS PARA O TRATAMENTO DE DOENÇAS NEURODEGENERATIVAS E MITOCONDRIAIS. A presente invenção refere-se a análogos de adenina, métodos de preparação de análogos de adenina, e métodos de tratamento de distúrbios associados com atividade de PINK1 cinase incluindo, mas não limitado a, doenças neurodegenerativas, doenças mitocondriais, fibrose e/ou cardiomiopatia utilizando estes análogos. Este resumo é pretendido como uma ferramenta de varredura para fins de busca na técnica particular e não se destina a ser limitante da presente invenção.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062980143P | 2020-02-21 | 2020-02-21 | |
PCT/US2021/019113 WO2021168446A1 (en) | 2020-02-21 | 2021-02-22 | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022016614A2 true BR112022016614A2 (pt) | 2022-12-13 |
Family
ID=77391353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022016614A BR112022016614A2 (pt) | 2020-02-21 | 2021-02-22 | Composições e métodos de uso dos mesmos para o tratamento de doenças neurodegenerativas e mitocondriais |
Country Status (15)
Country | Link |
---|---|
US (1) | US20240018146A1 (pt) |
EP (1) | EP4106874A4 (pt) |
JP (1) | JP2023515101A (pt) |
KR (1) | KR20220158290A (pt) |
CN (1) | CN115515682B (pt) |
AU (1) | AU2021222053A1 (pt) |
BR (1) | BR112022016614A2 (pt) |
CA (1) | CA3168531A1 (pt) |
CO (1) | CO2022013603A2 (pt) |
CR (1) | CR20220476A (pt) |
EC (1) | ECSP22074210A (pt) |
IL (1) | IL295681A (pt) |
MX (1) | MX2022010309A (pt) |
WO (1) | WO2021168446A1 (pt) |
ZA (1) | ZA202210409B (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112021019802A2 (pt) * | 2019-04-03 | 2021-12-07 | Mitokinin Inc | Composições e métodos de uso da mesma para tratamento de doença neurodegenerativa e mitocondrial |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9604361D0 (en) * | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
TW200508224A (en) * | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
CN110003216A (zh) * | 2006-02-02 | 2019-07-12 | 千禧药品公司 | E1活化酶抑制剂 |
EP2061772A4 (en) * | 2006-09-11 | 2011-06-29 | Curis Inc | MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES |
MX2011001821A (es) * | 2008-09-02 | 2011-03-25 | Sanofi Aventis | Aminoindanos sustituidos y sus analogos, y el uso farmaceutico de los mismos. |
CA2900779C (en) * | 2013-02-11 | 2021-10-26 | The Regents Of The University Of California | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy |
WO2018237145A1 (en) * | 2017-06-21 | 2018-12-27 | Mitokinin, Inc. | COMPOSITIONS AND METHODS USING THEM FOR THE TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE |
-
2021
- 2021-02-22 BR BR112022016614A patent/BR112022016614A2/pt unknown
- 2021-02-22 CA CA3168531A patent/CA3168531A1/en active Pending
- 2021-02-22 IL IL295681A patent/IL295681A/en unknown
- 2021-02-22 WO PCT/US2021/019113 patent/WO2021168446A1/en active Application Filing
- 2021-02-22 CN CN202180025593.5A patent/CN115515682B/zh active Active
- 2021-02-22 KR KR1020227032526A patent/KR20220158290A/ko unknown
- 2021-02-22 JP JP2022550119A patent/JP2023515101A/ja active Pending
- 2021-02-22 MX MX2022010309A patent/MX2022010309A/es unknown
- 2021-02-22 CR CR20220476A patent/CR20220476A/es unknown
- 2021-02-22 US US17/801,450 patent/US20240018146A1/en active Pending
- 2021-02-22 EP EP21757063.9A patent/EP4106874A4/en active Pending
- 2021-02-22 AU AU2021222053A patent/AU2021222053A1/en active Pending
-
2022
- 2022-09-20 ZA ZA2022/10409A patent/ZA202210409B/en unknown
- 2022-09-21 CO CONC2022/0013603A patent/CO2022013603A2/es unknown
- 2022-09-21 EC ECSENADI202274210A patent/ECSP22074210A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3168531A1 (en) | 2021-08-26 |
WO2021168446A1 (en) | 2021-08-26 |
EP4106874A4 (en) | 2024-03-20 |
EP4106874A1 (en) | 2022-12-28 |
CR20220476A (es) | 2023-05-31 |
CO2022013603A2 (es) | 2023-03-17 |
JP2023515101A (ja) | 2023-04-12 |
IL295681A (en) | 2022-10-01 |
KR20220158290A (ko) | 2022-11-30 |
ZA202210409B (en) | 2024-01-31 |
CN115515682B (zh) | 2024-06-21 |
ECSP22074210A (es) | 2023-02-28 |
US20240018146A1 (en) | 2024-01-18 |
AU2021222053A1 (en) | 2022-09-15 |
MX2022010309A (es) | 2022-11-14 |
CN115515682A (zh) | 2022-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2023000743A1 (es) | Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel | |
ECSP22041839A (es) | Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune | |
BR112019008458A2 (pt) | 1,2,4-triazolonas 2,4,5-trisubstituídas. | |
CL2018001089A1 (es) | Sales de valbenazina y polimorfos de las mismas. | |
BR112018073699A2 (pt) | amino lipídios de sulfonamida catiônica e amino lipídios zwiteriônico anfifílicos | |
BRPI0510074A (pt) | composições farmacêuticas para o tratamento de distúrbios sexuais ii | |
BRPI0909037B8 (pt) | compostos moduladores da atividade de tlr, e composição farmacêutica | |
BR112014018421A8 (pt) | Composições antimicrobianas compreendendo dgla, 15-ohepa e/ou 15-hetre e métodos de uso das mesmas | |
BR112015001847A8 (pt) | Composições e tratamento para doenças e distúrbios nos olhos | |
BR112019006113A2 (pt) | métodos de tratamento de distúrbios mitocondriais e metabólicos | |
CO2019010078A2 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
BR112022016614A2 (pt) | Composições e métodos de uso dos mesmos para o tratamento de doenças neurodegenerativas e mitocondriais | |
ECSP21036982A (es) | Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso | |
ECSP22080829A (es) | Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune | |
BR112021024380A2 (pt) | Formulações de liberação modificadas e usos das mesmas | |
BR112012017705A2 (pt) | derivados de sulfonamidas de 3,4-diarilpirazóis como inibidores da proteína cinase | |
DOP2022000121A (es) | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos | |
BR112015019802A2 (pt) | formulações farmacêuticas de nitrito e usos das mesmas | |
BR112019006880A2 (pt) | compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos | |
CA2904533C (en) | Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells | |
BR112021009078A8 (pt) | Antagonistas substituídos de receptor de adenosina de aminotriazolopirimidina e aminotriazolopirazina, composições farmacêuticas e seus usos | |
BR112014031706A2 (pt) | composição farmacêutica oral; forma de composição farmacêutica oral; método de redução de efeito de alimento de itraconazol em um indivíduo; método de redução de variabilidade em um mesmo indivíduo de itraconazol; método de redução de variabilidade entre indivíduos de itraconazol; método de tratamento de onicomicose; método de tratamento de uma doença ou afecção e método de tratamento de câncer | |
BR112019001301A2 (pt) | processo para controlar plantas daninhas | |
BR112022001700A2 (pt) | Método para tratar doença de alzheimer regulando-se o nível de aminoácidos | |
BR112021019702A2 (pt) | Remineralização de material dentário |